Android app Apple app link

H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90

By Yahoo! Finance   |   1 month ago
H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90

Halozyme Therapeutics (NASDAQ: HALO) is a promising biotech stock with a Buy rating and $90 price target. The company's recent trial success and growth potential make it an attractive investment choice.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.